This site is intended for health professionals only

Content funded and provided by GSK

For healthcare professionals only

Prescribing information is available via a link at the bottom of the page

Expert perspectives on NICE recommendations for initial maintenance therapy in COPD

GSK funded and organised a roundtable meeting with respiratory experts to discuss the health-system impact of LAMA/LABA initial maintenance therapy in COPD. Attendees were paid an honorarium for their time by GSK. Watch the videos below to learn more.
LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.

Why use LAMA/LABAs as initial maintenance therapy in specific COPD patients?

 
 
 
 

Expert perspectives on LAMA/LAMA initial maintenance therapy in COPD and real life case studies

GSK interviewed respiratory experts Dr Daryl Freeman and Laura Rush to discuss the use of LAMA/LABAs as initial maintenance therapy for appropriate symptomatic COPD patients and real life COPD case studies. The speakers were paid an honorarium for their time by GSK. Watch the videos below to learn more.
LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.

 

© NICE 2019 Chronic obstructive pulmonary disease in over 16s: non-pharmacological management and use of inhaled therapies. Available from
www.nice.org.uk/guidance/NG115 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication. For more information on the NICE COPD guidelines see www.nice.org.uk/guidance/NG115

AnoroEllipta (umeclidinium/vilanterol): prescribing information
IncruseEllipta (umeclidinium bromide): prescribing information
Relvar Ellipta (fluticasone furoate/vilanterol): prescribing information
TrelegyEllipta (fluticasone furoate/umeclidinium/vilanterol): prescribing information
Seretide (salmeterol/fluticasone propionate): prescribing information
Serevent (salmeterol): prescribing information
Ventolin (salbutamol): prescribing information

Adverse events should be reported. Reporting forms and information can be found
at yellowcard.mhra.gov.uk or search for MHRA Yellow card in the Google Play or Apple App store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

PM-GB-UCV-WCNT-200008 V2.0 | August 2020

© 2020 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
Anoro Ellipta was developed in collaboration with Innoviva.